Population-based laboratory surveillance of Hafnia alvei isolates in a large Canadian health region by Laupland, Kevin B et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Annals of Clinical Microbiology and 
Antimicrobials
Open Access Research
Population-based laboratory surveillance of Hafnia alvei isolates in a 
large Canadian health region
Kevin B Laupland*1,2,3,5, Deirdre L Church1,2,4, Terry Ross5 and 
Johann DD Pitout2,4
Address: 1Department of Medicine, University of Calgary and Calgary Health Region, Calgary Alberta, Canada, 2Department of Pathology and 
Laboratory Medicine, University of Calgary and Calgary Health Region, Calgary Alberta, Canada, 3Department of Critical Care Medicine, 
University of Calgary and Calgary Health Region, Calgary Alberta, Canada, 4Division of Microbiology, Calgary Laboratory Services, Calgary, 
Alberta, Canada and 5Centre for Anti-microbial Resistance, University of Calgary, Calgary Health Region, and Calgary Laboratory Services, Calgary, 
Alberta, Canada
Email: Kevin B Laupland* - kevin.laupland@calgaryhealthregion.ca; Deirdre L Church - deirdre.church@cls.ab.ca; 
Terry Ross - terry.ross@cls.ab.ca; Johann DD Pitout - johann.pitout@cls.ab.ca
* Corresponding author    
Abstract
Background: Hospital-based series have characterized Hafnia alvei primarily as an infrequent
agent of polymicrobial nosocomial infections in males with underlying illness.
Methods: We conducted population-based laboratory surveillance in the Calgary Health Region
during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-
microbial susceptibilities of Hafnia alvei isolates.
Results: A total of 138 patients with Hafnia alvei isolates were identified (2.1/100,000/year) and
two-thirds were of community onset. Older age and female gender were important risk factors for
acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower
respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-
microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/
clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.
Conclusion: Hafnia alvei was most commonly isolated as a mono-microbial etiology from the
urinary tract in women from the community. This study highlights the importance of population-
based studies in accurately defining the epidemiology of an infectious disease.
Introduction
Hafnia alvei has been recognized as an infrequent cause of
human infections [1]. A number of case reports and series
have identified this organism as an etiologic agent of uro-
genital, lower respiratory tract, intra-abdominal, and skin
and soft tissue infections as well as a cause of endop-
thalmitis and bacteremia without focus [2-6]. In the larg-
est previously reported clinical series to date, Gunthard
and Pennekamp reviewed 61 patients at two hospitals in
Zurich, Switzerland [2]. They found that in three quarters
of patients Hafnia alvei was isolated concurrently with
other bacteria, most patients were male, and that the
majority of isolates were associated with a respiratory tract
focus. Limited data exists investigating Hafnia alvei as an
agent of disease in the community [3-5].
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Because clinical series reported from selected clinics or
hospitals are potentially highly subject to selection bias,
they may provide misleading information regarding the
epidemiology of an infectious disease. Population-based
studies, where all cases of disease occurring in a defined
geographic region are studied, reduce this bias [7]. We
therefore conducted a population-based laboratory sur-
veillance study of all extra-intestinal Hafnia alvei isolates
in a large Canadian health region to define their inci-
dence, associated patient demographic risk factors, and
microbiology.
Methods
Study population
The Calgary Health Region (CHR) provides all publicly
funded healthcare services to the more than one million
population of the cities of Calgary and Airdre and numer-
ous adjacent surrounding communities covering an area
of 37,000 km2 [8]. Acute care is provided principally
through one pediatric and three major adult hospitals.
Nearly all (>95%) standard microbiology testing from
both community and hospital sites in the CHR is per-
formed by Calgary Laboratory Services (CLS). All patients
with Hafnia alvei isolates identified at hospital and com-
munity based collection sites within the CHR between
January 1, 2000 and December 31, 2005 were included in
this study. Because detailed clinical records were not
reviewed, individual written informed consent was not
obtained. For purposes of this study, patients were
assumed to be CHR residents and included in analysis if
they were outpatients with Alberta Personal Healthcare
numbers or if they were admitted to a CHR acute care
facility.
Population-based surveillance
Active, population-based surveillance for all Hafnia alvei
isolates obtained from patients in the CHR during the
study was performed by CLS. Hospitals, nursing homes,
physicians' offices, and community collection sites were
included in surveillance. Once Hafnia alvei isolates were
identified, basic laboratory and demographic information
was obtained from the regional laboratory information
system (PathNet Classic version 306, Cerner, Kansas City,
MO). Community isolates were classified as those submit-
ted from community based collection sites or those
within the first two days of admission to an acute care
facility; hospital isolates were those first isolated more
than two calendar days after hospital admission.
Clinical laboratory testing
Hafnia alvei was isolated using standard techniques; iden-
tification and susceptibilities to anti-microbial agents
were determined using Vitek (Vitek AMS; bioMérieux
Vitek Systems Inc., Hazelwood, MO.). Isolates were classi-
fied as to a primary focus of infection based on the avail-
able microbiology data. Patients with cultures from either
sputum, endotracheal aspirates, or bronchoalveolar lav-
age specimens were classified as lower respiratory foci,
urine cultures greater or equal to 107 cfu/L as urinary tract,
wounds or tissue specimens as soft tissue, and peritoneal
fluid or abdominal operative specimens as intra-abdomi-
nal foci. Bacteremia was defined by the isolation of Hafnia
alvei from at least one set of blood cultures and was clas-
sified as no focus or secondary to another focus if cultures
from other body sites were either concomitantly negative
or positive, respectively. Invasive infections were defined
by the isolation of Hafnia alvei from a normally sterile
body fluid or deep site.
Statistical analysis
All analyses were performed using Stata version 9.0 (Stata
Corp, College Station, TX). Differences in proportions
among categorical data were assessed using Fisher's exact
test. Medians with interquartile ranges (IQR) were used to
describe non-normally distributed continuous variables.
Incidence rates were calculated using regional demo-
graphic data as the denominator and compared using
Poisson counts. Category specific risks were calculated
and reported as risk ratios (RR) with exact 95% confidence
intervals (CI) as previously described [9].
Results
During the six years of surveillance, a total of 138 patients
with a Hafnia alvei isolate were identified for an overall
annual population incidence of 2.1 per 100,000 popula-
tion. The annual incidence of isolation varied considera-
bly during the years of the study as shown in Figure 1.
There was no seasonal pattern of occurrence evident. The
majority (93; 67%) were community isolates. Hospital
isolates were first identified a median of 13 (IQR; 6–33)
days after admission to hospital.
Annual incidence of hospital and community based isolation  of Hafnia alvei in the Calgary Health Region, 2000–2005 Figure 1
Annual incidence of hospital and community based isolation 
of Hafnia alvei in the Calgary Health Region, 2000–2005.
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The median age of the patients was 69 (IQR; 49–79) years.
There was a significant increase in the incidence associ-
ated with advancing age with the highest rate of 60 per
100,000 per year observed in those aged 90 years and
older as shown in Figure 2. Overall 106 (77%) of the
patients were female. The isolation rate was significantly
higher among females as compared to males (3.2 vs. 1.0
per 100,000; RR 3.3; 95% CI, 2.20–5.07; p < 0.0001) over-
all, and this was most pronounced among those aged 90
years and older (Figure 2). As compared to females, males
were much more likely to have hospital isolates (19/32;
59% vs. 26/106; 25%, RR 2.4; 95% CI 1.56–3.76; p <
0.001). Among the 19 hospital isolates in males, 8 were
classified as urine, 7 lower respiratory, 2 soft tissue, and 1
each as intra-abdominal and bacteremia without focus. In
contrast, in the 26 hospital isolates from women all but 3
were from urine; 2 were intra-abdominal and 1 was bac-
teremia without focus.
The most common focus of isolation was urine in 112
(81%), followed by lower respiratory tract in 10 (7%),
and soft tissue in 5 (4%). The foci of isolation in associa-
tion with other demographic and clinical variables are
shown in Table 1. The annual incidence of non-urinary
foci observed in females of 0.36 per 100,000 was compa-
rable to the incidence in males of 0.42 per 100,000 (RR
0.85; 95% CI, 0.36–1.89; p = 0.7). Fourteen patients had
invasive infections for an incidence of 0.21 per 100,000/
year; nine of these were bacteremias (6 no focus and 3 uri-
nary tract) and five were intra-peritoneal samples.
In the majority of cases (94; 68%) Hafnia alvei was iso-
lated from clinical samples as a mono-microbial etiology,
and this was significantly associated with the focus of iso-
lation (Table 1, p < 0.001). Non-urinary tract foci were
more than three-times more likely to be poly-microbial as
compared to the urinary tract isolates [19/26 (73%) vs.
25/112 (22%); RR 3.3; 95% CI, 2.16–4.97; p < 0.0001]. In
the 44 patients who had polymicrobial cultures, the co-
isolates included Enterococcus species in 17, Escherichia coli
in 9, Klebsiella species in 6, Staphylococcus aureus in 4, Pseu-
domonas aeruginosa in 3, Candida species in 3, Citrobacter
species in 3, group B streptococcus in 2, and 1 each of
Enterobacter cloacae, Haemophilus influenzae, streptococcus
milleri group, and Bacteroides fragilis.
The majority of Hafnia alvei isolates were resistant to amp-
icillin (111;80%), cephalothin (106; 77%), amoxicillin/
clavulanate (98; 71%), and cefazolin (95; 69%). Lower
rates of resistance were seen with cefpodoxime (56; 41%),
gentamicin (12; 9%), cefuroxime (15; 11%), piperacillin/
tazobactam (15; 11%), ceftazidime (9; 7%), ceftriaxone
(8; 6%), nitrofurantoin (4; 3%), and trimethoprim-sul-
famethoxazole (2; 1%). None of the isolates demon-
strated resistance to either imipenem or ciprofloxacin.
Overall 20 (14%) of isolates were susceptible to all the
above anti-microbial agents tested. Female patients (19/
106;18% vs. 1/32; 3% for males; p = 0.04), urinary tract
focus (19/112; 17% vs. 1/26; 4%; p = 0.1), and commu-
nity isolates (20/93; 22% vs. 0/42 for hospital onset, p <
0.001) were associated with culturing fully susceptible
strains.
Discussion
The findings of our study challenge many of the currently
held beliefs surrounding the epidemiology of Hafnia alvei
infections. The limited body of pre-existing literature is
composed primarily of hospital-based case reports and
series [2-6]. These in general report that Hafnia alvei most
commonly infects men, that it typically causes disease in
association with other organisms as a poly-microbial eti-
ology, that it is a predominantly nosocomial pathogen,
and that the respiratory and gastrointestinal tracts are the
Table 1: Features of Hafnia alvei isolation according to focus.
Source Age (interquartile range) Female Hospital isolation Polymicrobial etiology
Urine (n = 112) 69 (46–80.5) 94 (84%) 31 (28%) 25 (22%)
Lower respiratory (n = 10) 64 (51–76) 2 (20%) 7 (70%) 7 (70%)
Soft tissue (n = 5) 61 (60–66) 3 (60%) 2 (40%) 4 (80%)
Bacteremia without focus (n = 6) 78.5 (74–84) 3 (50%) 2 (33%) 4 (67%)
Intra-abdominal (n = 5) 62 (47–73) 4 (80%) 3 (60%) 4 (80%)
Age and gender specific incidence rates of Hafnia alvei isola- tion in the Calgary Health Region, 2000–2005 (F = Female; M  = Male) Figure 2
Age and gender specific incidence rates of Hafnia alvei isola-
tion in the Calgary Health Region, 2000–2005 (F = Female; M 
= Male).
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most common sites of isolation. In contrast, we demon-
strated that in a non-selected population that these infec-
tions are typically mono-microbial in nature, are more
common in females, and that the large majority are com-
munity-onset urinary tract infections. The dramatic differ-
ence seen in our study compared to others likely reflects at
least in part the selection bias in those studies largely
resulting from their restriction to patients hospitalized in
university-based acute care centres. In comparison, we
studied all Hafnia alvei isolated from patients in our
region including from hospitals, physician's offices, clin-
ics, nursing homes, and urgent care centres.
This study documents the rarity of infections due to Haf-
nia alvei, with an overall annual isolation rate of 2 per
100,000 population and an incidence of 0.18 per 100,000
for invasive disease. To put this in context, the rate of inva-
sive Hafnia alvei disease is approximately 100-fold lower
than that reported for invasive pneumococcal (20–22 per
100,000) and Staphylococcus aureus disease (28 per
100,000) [9-11], and 10-fold lower than invasive Candida
species infections (2.9 per 100,000) [12]. In contrast, our
rate of Hafnia alvei bacteremia is nearly twice that previ-
ously thought based on crude estimates from the United
Kingdom [1]. The higher incidence of Hafnia alvei isola-
tion observed among females as compared to males (Fig-
ure 2) was largely due the dramatically higher rate of
urinary foci seen among females (Table 1). We did
observe substantial variability in the yearly isolation of
Hafnia alvei with a spike in 2005 (Figure 1). While some
of this may reflect natural variability, the apparent
increase in 2005 remains unexplained by our data. Fur-
ther investigation using a molecular typing method such
as pulsed field gel electrophoresis would be required to
assess for the presence of a clonal outbreak in that year.
Although our study reports novel population incidence
rates for Hafnia alvei isolation, there are a few methodo-
logical aspects of our incidence determinations that merit
discussion. Despite the fact that our study was unlikely to
miss any significant number of cases of culture positive
disease occurring in the CHR because virtually all micro-
biology laboratory services were included in surveillance,
we likely overestimated the occurrence of disease due to
Hafnia alvei as a result of two potential reasons. First,
because we did not have clinical data to confirm the clin-
ical significance of cultures, we likely included a number
of patients that were not truly infected but rather colo-
nized [1]. However, this was not an issue as regards inva-
sive disease as these are by definition rarely, if ever,
contaminants. Second, we did not confirm residency sta-
tus of cases in this study but rather assumed that patients
who had Alberta Health numbers as outpatients or where
admitted to hospital were residents. We have previously
shown that inclusion of non-residents to be an important
bias at least in population-based studies in critically ill
patients where referral is common [13]. Based on our
experience with a range of population-based studies in
our region, we estimate that we may have included
approximately 15–20% non-residents. It is important to
note that each of the limitations noted in our study would
have the effect of overestimation of the true incidence
rate; in any case these data therefore demonstrate that
Hafnia alvei infections are truly uncommon.
Prior case reports and series have noted that isolation of
Hafnia alvei appears to occur frequently in association
with co-morbid illnesses such as malignancies and
chronic heart, liver, and lung disease [2,5]. Since the prev-
alence of co-morbid illnesses tends to increase with
advancing age, our observations that the very old were at
highest risk for isolating Hafnia alvei may provide indirect
support for this. However, in order to define whether cer-
tain underlying conditions are actual risk factors for dis-
ease, knowledge of both the frequency of that factor
among cases of disease in addition to the rate in a control
population is required. No studies to date, including ours,
have been adequately designed to establish risk factors for
Hafnia alvei infection and further study is required.
Similar to the existing literature, we observed high rates of
resistance to ampicillin, amoxicillin/clavulanate, cepha-
lothin, and cefazolin, low rates of resistance to aminogly-
cosides, and second and third generation cephalosporins,
and no isolates that demonstrated resistance to imipenem
or ciprofloxacin [2,5,14]. Hafnia alvei is known to encode
an AmpC-type β-lactamase that is distinct from many
other Enterobacteriaceae that results in resistance to third
generation cephalosporins [15,16]. Approximately one-
quarter of our isolates were susceptible to ampicillin and
cephalothin suggesting that these isolates do not produce
an AmpC-type β-lactamase or do not express their
enzymes in sufficient quantities to cause resistance.
In summary, we present the first population-based study
investigating the epidemiology of Hafnia alvei infections
and document that these infections are uncommon. We
demonstrate that this organism is most commonly iso-
lated from the urine of community-based patients and
that females and the elderly are at highest risk. This study
defines the distribution and determinants of Hafnia alvei
isolation in a population at large and highlights the
importance of population-based studies in accurately
defining the epidemiology of an infectious disease.
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